^
    3d
    Indocyanine Green-Labeled Antibodies Cotargeting CDCP1 and Mesothelin for Fluorescence-Guided Imaging of Pancreatic Cancer. (PubMed, Mol Pharm)
    Quantitative ex vivo fluorescence analysis of excised xenografts demonstrated that combining ch10D7ICG and amatuximabICG enhances tumor-associated fluorescence by 2.8- to 12.5-fold compared with either agent alone. The results support the potential of dual-targeted, antibody-based fluorescence imaging for enhanced intraoperative visualization and excision of PDAC, including for tumors with heterogeneous expression of either or both of the targeted receptors CDCP1 and MSLN.
    Journal
    |
    MSLN (Mesothelin) • CDCP1 (CUB Domain Containing Protein 1)
    |
    amatuximab (MORAb-009)
    1m
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, Amgen | N=220 --> 37 | Trial completion date: Feb 2028 --> Apr 2026 | Trial primary completion date: Jun 2027 --> Apr 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    2ms
    A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=262, Recruiting, Sichuan Huiyu Pharmaceutical Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors. (PubMed, ESMO Open)
    MSLN-TTC showed good tolerability, but the maximum tolerated dose could not be determined due to discontinuations after antidrug antibody formation. Stable disease was observed in 12 out of 36 patients.
    P1 data • Journal • First-in-human
    |
    MSLN (Mesothelin)
    |
    thorium (227Th) anetumab corixetan (BAY 2287411)
    3ms
    Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model. (PubMed, J Pharmacokinet Pharmacodyn)
    Model was developed based on digitized individual level CK, categorical antitumor activity and percentage tumor antigen expression dataset from following phase-1 dose-escalation studies: (A) anti-mesothelin CAR-T in multiple cancer indications (n = 15, cohorts w/ and w/o LDC), (B) gavocabtagene autoleucel (n = 7, w/ and w/o LDC) in multiple indications, (C) anti-glypican 3 CAR-T in advanced hepatocellular carcinoma (n = 13, dose-range 0.7-5.18 billion) and (D) anti-PSMA/TGFβ CAR-T in prostate cancer (n = 10, w/ and w/o LDC)...Using model simulation, CAR-T cell expansion was found to be dependent on initial tumor burden and antigen positive tumor fraction. The developed PBPK-PD model could be leveraged as an effective tool in future to provide mechanistic understanding on CK-PD behavior of cell therapies targeting solid tumors.
    Journal • IO biomarker
    |
    GPC3 (Glypican 3) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    gavocabtagene autoleucel (TC-210)
    3ms
    ZWI-ZW171-10: A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers (clinicaltrials.gov)
    P1, N=32, Terminated, Zymeworks BC Inc. | N=160 --> 32 | Trial completion date: Dec 2027 --> Oct 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2027 --> Sep 2025; Sponsor decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    5ms
    ZWI-ZW171-10: A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers (clinicaltrials.gov)
    P1, N=160, Active, not recruiting, Zymeworks BC Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    5ms
    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (clinicaltrials.gov)
    P1/2, N=57, Active, not recruiting, TCR2 Therapeutics | N=36 --> 57 | Trial primary completion date: Nov 2028 --> Nov 2024
    Enrollment change • Trial primary completion date • IO biomarker
    |
    MSLN (Mesothelin)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV
    6ms
    A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=262, Not yet recruiting, Sichuan Huiyu Pharmaceutical Co., Ltd
    New P1/2 trial
    6ms
    A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=35, Completed, Janssen Research & Development, LLC | Active, not recruiting --> Completed | Trial completion date: Sep 2025 --> Jun 2025 | Trial primary completion date: Sep 2025 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    8ms
    A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2028 --> Sep 2025 | Trial primary completion date: Feb 2026 --> Sep 2025
    Trial completion date • Trial primary completion date
    8ms
    CT-95 in Advanced Cancers Associated With Mesothelin Expression (clinicaltrials.gov)
    P1, N=70, Recruiting, Context Therapeutics Inc. | N=50 --> 70
    Enrollment change
    |
    CT-95